Anaplastic thyroid cancer

Medicina Sperimentale

Medicina Sperimentale

L'attività del gruppo di ricerca è di natura traslazionale e rivolta all'identificazione: i) di nuovi marcatori molecolari e clinico-patologici utili in sede diagnostica e prognostica dei tumori endocrini; ii) di nuovi bersagli terapeutici per la terapia delle forme più aggressive di carcinomi tiroidei; iii) dei meccanismi molecolari coinvolti nell'associazione fra patologie tiroidee e malattie cutanee, così come nell'associazione fra patologie tiroidee e altre neoplasie (i.e. tumori della mammella, etc.).

Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo

The antitumor activity of vandetanib [a multiple signal transduction inhibitor including the RET tyrosine kinase, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptor (VEGFR), ERK and with antiangiogenic activity], in primary anaplastic thyroid cancer (ATC) cells, in the human cell line 8305C [undifferentiated thyroid cancer (TC)] and in an ATC-cell line (AF), was investigated in the present study.

Recent advances in precision medicine for the treatment of anaplastic thyroid cancer

Introduction: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies (representing 15–40% of fatal TC cases), classified as stage IV by the American Joint Committee on Cancer, regardless of tumor size or presence of lymph node and distant metastases. A large number of genetic alterations are associated with ATC, especially causing dysfunctions in the ERK1/2-MEK1/2 and PI3K-AKT signaling pathways (BRAF, p53, RAS, EGFR, VEGFR1, VEGFR2, chromosomal rearrangements, etc). New drugs targeting these molecular pathways have recently been evaluated in ATC.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma